Loading clinical trials...

Two Cycles VS Three Cycles Induction Chemotherapy in T1-4N2-3 Locally Advanced Nasopharyngeal Carcinoma | Clinical Trials | Clareo Health

RECRUITINGPHASE3

Two Cycles VS Three Cycles Induction Chemotherapy in T1-4N2-3 Locally Advanced Nasopharyngeal Carcinoma

Two Cycles VS Three Cycles Induction Chemotherapy Plus Concurrent Chemoradiotherapy in T1-4N2-3 Locally Advanced Nasopharyngeal Carcinoma

NCT05860868•First Affiliated Hospital, Sun Yat-Sen University

View on ClinicalTrials.gov

Summary

This trial is a multi-center phase III clinical trial. The purpose of this trial is to explore whether 2 cycles induction chemotherapy combined with concurrent chemoradiotherapy is not inferior to 3 cycles induction chemotherapy combined with concurrent chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma.

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Age 18-65 years old;
•2. Pathologically confirmed non-keratinizing nasopharyngeal carcinoma;
•3. Stage T3-4N0-1 (according to the UICC/AJCC 8th);
•4. No distant metastasis;
•5. Have not received anti-cancer treatment in the past;
•6. ECOG (Eastern Cooperative Oncology Group of the United States): 0-1;
•7. Adequate hematologic, hepatic and renal function.

Exclusion Criteria

•1. The purpose of treatment is palliative;
•2. Diagnosed with other malignant tumors at the same time;
•3. Malignant tumor history;
•4. Pregnancy or breastfeeding, or expect to become pregnant during the clinical trial period;
•5. Combined serious illness.

Locations (1)

First Affiliated Hospital, Sun Yat-Sen University

Guangzhou, Other (Non U.s.), China

Key Dates

Start Date

May 1, 2023

Primary Completion Date

May 1, 2028

Completion Date

May 1, 2030

Last Updated

May 16, 2023

Enrollment

474

ESTIMATED participants

Conditions

Locally Advanced Nasopharyngeal Carcinoma

Interventions

2 cycles induction chemotherapy

DRUG

3 cycles induction chemotherapy

DRUG

Contacts

Cheng-Tao Wang

CONTACT

+862087755766 wangcht5@mail.sysu.edu.cn

Envafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial.

NCT05397769

Locally Advanced Nasopharyngeal CarcinomaEnvafolimab+2 more

View study

NOT_YET_RECRUITINGPHASE3

Serplulimab Combined With Induction Chemotherapy and Radiotherapy in Nasopharyngeal Carcinoma

NCT07177443

Locally Advanced Nasopharyngeal Carcinoma

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 16, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Two Cycles VS Three Cycles Induction Chemotherapy in T1-4N2-3 Locally Advanced Nasopharyngeal Carcinoma

Inclusion Criteria

Exclusion Criteria

Envafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial.

Serplulimab Combined With Induction Chemotherapy and Radiotherapy in Nasopharyngeal Carcinoma

GP Combined With Nimotuzumab and Sintilimab as Induction Therapy for Nasopharyngeal Carcinoma

GP Induction Chemotherapy us TPF Adjuvant Chemotherapy Combined With DDP Concurrent Chemoradiotherapy in the Treatment of Locally Advanced NPC